Table 3 Baseline characteristics of COVID-19 patients with PPI and H2RA in the secondary analysis
Characteristics, % | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
PPI users (n = 420) | H2RA users (n = 840) | Absolute standardized difference | PPI users (n = 410) | H2RA users (n = 804) | Absolute standardized difference | |
Age group, % | ||||||
18–19 | < 1.2 | 1.7 | 0.06 | < 1.2 | 1.7 | 0.06 |
20–24 | 4.8 | 10.4 | 0.21 | 4.9 | 4.8 | 0.01 |
25–29 | 4.5 | 8.1 | 0.15 | 4.6 | 4.3 | 0.02 |
30–34 | 4.0 | 2.9 | 0.06 | 4.1 | 4.0 | 0.01 |
35–39 | 2.6 | 7.0 | 0.21 | 2.7 | 2.8 | 0.01 |
40–44 | 3.1 | 5.2 | 0.11 | 3.2 | 3.7 | 0.03 |
45–49 | 5.7 | 7.5 | 0.07 | 5.9 | 4.7 | 0.05 |
50–54 | 12.1 | 8.3 | 0.13 | 12.2 | 11.2 | 0.03 |
55–59 | 12.1 | 10.7 | 0.04 | 12.4 | 12.2 | 0.01 |
60–64 | 16.7 | 10.1 | 0.19 | 16.3 | 13.1 | 0.09 |
65–69 | 10.2 | 7.3 | 0.10 | 10.0 | 9.6 | 0.01 |
70–74 | 6.9 | 6.4 | 0.02 | 6.8 | 7.8 | 0.04 |
75–79 | 7.1 | 6.5 | 0.02 | 7.3 | 8.9 | 0.06 |
80–84 | 4.5 | 3.8 | 0.04 | 4.4 | 5.2 | 0.04 |
85–89 | 3.3 | 3.0 | 0.02 | 2.9 | 4.4 | 0.08 |
Gender: female, % | 60.7 | 66.8 | 0.08 | 61.0 | 65.9 | 0.02 |
Medical history: general, % | ||||||
Chronic obstructive lung disease | < 0.1 | < 0.1 | < 0.1 | < 0.1 | 0.12 | 0.09 |
Chronic kidney disease | < 0.1 | < 0.1 | 0.11 | < 0.1 | < 0.1 | 0.09 |
Charlson comorbidity index | 3.0 | 2.3 | 0.27 | 3.0 | 2.7 | 0.1 |